Special Issue "Advances and Research Progress in Hepatocellular Carcinoma"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2012)
Ms. Candy Wan
MDPI Beijing Office, Suite 2011, Ruidu International Center, No. 1 Cuijingbeili, Tongzhou District, Beijing, China
Phone: +86 10 81521170
Fax: +86 10 59011089
Dear Colleagues,This special issue of Cancers discusses the many facets and different perspectives of the recent advances and research progress in hepatocellular Carcinoma. This is timely considering the several improvements in managing this disease starting with curative therapies, local ones, and novel systemic treatments.
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- hepatocellular carcinoma
- hepatitis C
- hepatitis B
- liver transplant
- radifrequency ablation
- clinical trials
Cancers 2012, 4(2), 323-339; doi:10.3390/cancers4020323
Received: 6 December 2011; in revised form: 14 February 2012 / Accepted: 21 March 2012 / Published: 23 March 2012| Download PDF Full-text (670 KB) | Download XML Full-text
Review: A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Cancers 2012, 4(2), 354-378; doi:10.3390/cancers4020354
Received: 13 February 2012; in revised form: 15 March 2012 / Accepted: 26 March 2012 / Published: 5 April 2012| Download PDF Full-text (218 KB) | Download XML Full-text
Review: Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials
Cancers 2012, 4(2), 549-565; doi:10.3390/cancers4020549
Received: 8 May 2012; in revised form: 25 May 2012 / Accepted: 30 May 2012 / Published: 5 June 2012| Download PDF Full-text (163 KB) | Download XML Full-text
Article: The Expression of Embryonic Liver Development Genes in Hepatitis C Induced Cirrhosis and Hepatocellular Carcinoma
Cancers 2012, 4(3), 945-968; doi:10.3390/cancers4030945
Received: 23 July 2012; in revised form: 9 August 2012 / Accepted: 13 September 2012 / Published: 18 September 2012| Download PDF Full-text (263 KB) | Download XML Full-text
Last update: 25 September 2012